PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25213670-6 2014 In cisplatin-resistant cells with higher Jak2 and STAT3 expression, cisplatin and ruxolitinib combination dramatically suppressed the cell growth, down-regulated the expression of phosphorylated STAT3 and induced cleaved caspase-3 expression. ruxolitinib 82-93 signal transducer and activator of transcription 3 Homo sapiens 50-55 26356819-3 2015 In support of this hypothesis, we found that, in HEL JAK2(V617F) cells, ruxolitinib treatment decreased STAT3 and Stathmin 1 association, induced Stathmin 1 activation and microtubule instability. ruxolitinib 72-83 signal transducer and activator of transcription 3 Homo sapiens 104-109 25749974-2 2015 Their analyses implicate constitutive activation of STAT3 in both malignant and nonmalignant bone marrow cell populations as a driver of aberrant cytokine secretion and as a cellular target mediating the therapeutic activity of ruxolitinib. ruxolitinib 228-239 signal transducer and activator of transcription 3 Homo sapiens 52-57 25213670-6 2014 In cisplatin-resistant cells with higher Jak2 and STAT3 expression, cisplatin and ruxolitinib combination dramatically suppressed the cell growth, down-regulated the expression of phosphorylated STAT3 and induced cleaved caspase-3 expression. ruxolitinib 82-93 signal transducer and activator of transcription 3 Homo sapiens 195-200 24497534-4 2014 Macrophage polarization was signal transducer and activator of transcription 3 dependent and was impaired by the Janus kinase inhibitor ruxolitinib. ruxolitinib 136-147 signal transducer and activator of transcription 3 Homo sapiens 28-78 24778152-6 2014 Incubation of CLL cells with the JAK1/2 inhibitor ruxolitinib inhibited IgM-induced STAT3 phosphorylation and induced apoptosis of IgM-stimulated but not unstimulated CLL cells in a dose- and time-dependent manner. ruxolitinib 50-61 signal transducer and activator of transcription 3 Homo sapiens 84-89 34694880-4 2022 Ruxolitinib pharmacodynamics were assessed by inhibition of phosphorylation of signal transducer and activator of transcription 3 (pSTAT3). ruxolitinib 0-11 signal transducer and activator of transcription 3 Homo sapiens 79-129 34396051-10 2021 Consistently, the AXL inhibitor bemcentinib exerted additive effects with ruxolitinib via impaired STAT3, STAT5, and AKT signaling. ruxolitinib 74-85 signal transducer and activator of transcription 3 Homo sapiens 99-104 33517393-9 2021 Interestingly, the STAT3 phosphorylation could be inhibited with ruxolitinib as well as tofacitinib, which are clinically approved JAK1 and JAK3 (to lesser extent JAK2 and JAK1) inhibitors, respectively. ruxolitinib 65-76 signal transducer and activator of transcription 3 Homo sapiens 19-24 35507130-8 2022 Ex vivo treatment with the JAK1/2-inhibitor ruxolitinib reduced cytokine responsiveness and normalized STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient" cells. ruxolitinib 44-55 signal transducer and activator of transcription 3 Homo sapiens 131-136 33517393-10 2021 Given our results and the recent reports of ruxolitinib and tofacitinib use for the treatment of diseases caused by direct activation of STAT3 or STAT1 we speculate that these drugs may be effective in the treatment of our patient"s condition. ruxolitinib 44-55 signal transducer and activator of transcription 3 Homo sapiens 137-142 33490193-6 2020 The high level of IL-6 enhanced C2C12 myotube atrophy through the activation of JAK/STAT3, while inhibiting JAK/STAT3 pathway by ruxolitinib (a JAK1/2 inhibitor) or C188-9 (a STAT3 inhibitor) significantly attenuated C2C12 myotube atrophy induced by IL-6. ruxolitinib 129-140 signal transducer and activator of transcription 3 Homo sapiens 112-117 33548083-10 2021 Moreover, SHARPIN-mediated expression of IL-33 was reduced after treatment of HaCaT cells with the JAK/STAT inhibitor ruxolitinib. ruxolitinib 118-129 signal transducer and activator of transcription 3 Homo sapiens 103-107 33052714-9 2021 Therefore, we propose that ruxolitinib may present a novel therapeutic option for PAH patients by reducing pulmonary vascular remodeling through effectively blocking Jak2-Stat3 mediated signaling pathways. ruxolitinib 27-38 signal transducer and activator of transcription 3 Homo sapiens 171-176 33662027-4 2021 Although ruxolitinib inhibited hyperactivity in the scratch assay in keloid fibroblasts, it paradoxically exacerbated the hyper-glycolytic state, possibly by further limiting OxPhos via alterations in mitochondrial phosphorylated STAT3 (pSTAT3Ser727). ruxolitinib 9-20 signal transducer and activator of transcription 3 Homo sapiens 230-235 33465556-6 2021 Notably, STAT3 knockdown or upstream inhibition through the JAK1/2 kinase inhibitor ruxolitinib prevented opioid-induced breast cancer cell metastasis and migration in vitro and in vivo. ruxolitinib 84-95 signal transducer and activator of transcription 3 Homo sapiens 9-14 33490193-6 2020 The high level of IL-6 enhanced C2C12 myotube atrophy through the activation of JAK/STAT3, while inhibiting JAK/STAT3 pathway by ruxolitinib (a JAK1/2 inhibitor) or C188-9 (a STAT3 inhibitor) significantly attenuated C2C12 myotube atrophy induced by IL-6. ruxolitinib 129-140 signal transducer and activator of transcription 3 Homo sapiens 112-117 32844992-8 2020 JAK inhibitor ruxolitinib inhibited STAT3 phosphorylation in MM cell lines, upregulated CD38 expression in MM cell lines and primary patient MM cells, and augmented DARA-mediated ADCC against MM cell lines. ruxolitinib 14-25 signal transducer and activator of transcription 3 Homo sapiens 36-41 32944850-0 2020 Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient. ruxolitinib 0-11 signal transducer and activator of transcription 3 Homo sapiens 59-64 32022429-0 2020 LPS-induced inflammation desensitizes hepatocytes to Fas-induced apoptosis through Stat3 activation-The effect can be reversed by ruxolitinib. ruxolitinib 130-141 signal transducer and activator of transcription 3 Homo sapiens 83-88 32962959-10 2021 DPI combined with ruxolitinib increased PARP1 cleavage in SET2 cells and potentiated ruxolitinib-reduced STAT3, STAT5 and S6 ribosomal protein in HEL cells. ruxolitinib 18-29 signal transducer and activator of transcription 3 Homo sapiens 105-110 32962959-10 2021 DPI combined with ruxolitinib increased PARP1 cleavage in SET2 cells and potentiated ruxolitinib-reduced STAT3, STAT5 and S6 ribosomal protein in HEL cells. ruxolitinib 85-96 signal transducer and activator of transcription 3 Homo sapiens 105-110 32047890-0 2020 Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. ruxolitinib 0-11 signal transducer and activator of transcription 3 Homo sapiens 85-90 31837586-10 2020 Antagonism of JAK/STAT3 by ruxolitinib abrogated benefits in ATM pathway-mediated DNA repair; and identification of the ruxolitinib-sensitive component of cytoprotection allowed separations of these pathway intersections. ruxolitinib 27-38 signal transducer and activator of transcription 3 Homo sapiens 18-23 32758351-6 2020 Chemical inhibition of JAK1 in COV434 cells with 100nM ruxolitinib for 72h resulted in significant increases in STAT3 mRNA (P=0.034) and p-Y701-STAT1 protein (P=0.0117), demonstrating a role for JAK1 in modulating STAT in granulosa cells. ruxolitinib 55-66 signal transducer and activator of transcription 3 Homo sapiens 112-117 32234672-6 2020 IL-22 was next found to activate the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 3 pathway, whose inhibition by the JAK inhibitor ruxolitinib fully prevented the IL-22-mediated CYP3A4, CYP2B6 and NTCP repression in HepaRG cells. ruxolitinib 161-172 signal transducer and activator of transcription 3 Homo sapiens 56-113 32330554-7 2020 The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway inhibitor ruxolitinib effectively suppressed the effects of LINC00691. ruxolitinib 106-117 signal transducer and activator of transcription 3 Homo sapiens 71-75 32022429-6 2020 Pre-treatment with ruxolitinib, a selective Janus kinase (JAK) 1/2 inhibitor, prevented the LPS-induced Stat3 phosphorylation and restored the sensitivity of hepatocytes to Fas-mediated apoptosis. ruxolitinib 19-30 signal transducer and activator of transcription 3 Homo sapiens 104-109 31147469-6 2019 Finally, we demonstrate that STAT3 deletion and JAK/STAT inhibition in macrophages increases expression of the protumorigenic factor cyclooxygenase-2 (COX-2), and that COX-2 inhibition enhances responsiveness of tumors to ruxolitinib. ruxolitinib 222-233 signal transducer and activator of transcription 3 Homo sapiens 29-34 31452174-5 2020 Ruxolitinib treatment resulted in the production of IL-6 and active formation of IL-6 receptor complex for the subsequent activation of the IL-6R/JAK2/STAT3 axis. ruxolitinib 0-11 signal transducer and activator of transcription 3 Homo sapiens 151-156 31452174-10 2020 Additionally, both miR-17a-3p and miR-20a overexpression induced by ruxolitinib treatment may be playing a major role in downregulated JAK2, STAT3, and PI3K proteins. ruxolitinib 68-79 signal transducer and activator of transcription 3 Homo sapiens 141-146 31182137-14 2019 Transcriptome analyses revealed that STAT1 and STAT3 activation enable AKR1C1-induced cisplatin-resistance and can be overcome by ruxolitinib treatment. ruxolitinib 130-141 signal transducer and activator of transcription 3 Homo sapiens 47-52 30930994-7 2019 Ruxolitinib, a potent JAK2 inhibitor, was demonstrated to attenuate STAT3 phosphorylation and the proliferation of TAMR-MCF-7 cells. ruxolitinib 0-11 signal transducer and activator of transcription 3 Homo sapiens 68-73 30557559-0 2019 Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function Mutation. ruxolitinib 12-23 signal transducer and activator of transcription 3 Homo sapiens 89-94 30340199-7 2018 Plasma inhibitory assay results revealed a decrease in phospho-STAT3 levels after treatment with ruxolitinib. ruxolitinib 97-108 signal transducer and activator of transcription 3 Homo sapiens 63-68 28722170-9 2017 This effect was inhibited by the JAK1/2 inhibitor of the JAK/STAT3 pathway ruxolitinib. ruxolitinib 75-86 signal transducer and activator of transcription 3 Homo sapiens 61-66 30123428-7 2018 Next, we investigated the effects of ruxolitinib, an inhibitor of both JAK1 and JAK2, which phosphorylates and activates STAT3. ruxolitinib 37-48 signal transducer and activator of transcription 3 Homo sapiens 121-126 30123428-8 2018 Ruxolitinib suppressed the phosphorylation of STAT3 in EBV-positive T- or NK-cell lines. ruxolitinib 0-11 signal transducer and activator of transcription 3 Homo sapiens 46-51 29228628-7 2017 Luminespib decreased the phosphorylation of mutant STAT3 at Y705, whereas JAK1/JAK2 inhibitor ruxolitinib had reduced efficacy on mutant STAT3 phosphorylation. ruxolitinib 94-105 signal transducer and activator of transcription 3 Homo sapiens 137-142 28784136-17 2017 These results further suggest that inhibition of STAT3 phosphorylation in the RAB3C-IL-6-STAT3 axis by using Ruxolitinib may be a new therapeutic strategy to combat metastatic colon cancers. ruxolitinib 109-120 signal transducer and activator of transcription 3 Homo sapiens 49-54 28684419-6 2017 Enhancement is accompanied by an increase in signal transducer and activator of transcription 5 (STAT5) phosphorylation and is abrogated by treatment with C188-9, a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor. ruxolitinib 192-203 signal transducer and activator of transcription 3 Homo sapiens 165-172 28784136-17 2017 These results further suggest that inhibition of STAT3 phosphorylation in the RAB3C-IL-6-STAT3 axis by using Ruxolitinib may be a new therapeutic strategy to combat metastatic colon cancers. ruxolitinib 109-120 signal transducer and activator of transcription 3 Homo sapiens 89-94 28463395-7 2017 The effect on auto-antibody production was dependent on STAT-3 activation as it was abrogated in the presence of the JAK/STAT-3 pathway inhibitors ruxolitinib and stattic. ruxolitinib 147-158 signal transducer and activator of transcription 3 Homo sapiens 56-62 28463395-7 2017 The effect on auto-antibody production was dependent on STAT-3 activation as it was abrogated in the presence of the JAK/STAT-3 pathway inhibitors ruxolitinib and stattic. ruxolitinib 147-158 signal transducer and activator of transcription 3 Homo sapiens 121-127 28053127-7 2017 Suppression of JAK1/2 by ruxolitinib prevented STAT3-mediated transcription of ZEB1, SNAI1 and OSMR, as well as the emergence of a mesenchymal/CSC phenotype. ruxolitinib 25-36 signal transducer and activator of transcription 3 Homo sapiens 47-52 27379204-4 2016 The combination of (ruxolitinib + ERBB1/2/4 inhibitor) rapidly inactivated AKT, mTORC1, mTORC2, STAT3, and STAT5, and activated eIF2alpha. ruxolitinib 20-31 signal transducer and activator of transcription 3 Homo sapiens 96-101 27579615-4 2016 The JAK1/2 inhibitor ruxolitinib blocked STAT3-phosphorylation and partially improved DEX-mediated killing of stimulated CLL cells in vitro but not in CLL patients in vivo. ruxolitinib 21-32 signal transducer and activator of transcription 3 Homo sapiens 41-46 27474009-18 2016 Ruxolitinib can inhibit JAK and prevent STAT3 activation. ruxolitinib 0-11 signal transducer and activator of transcription 3 Homo sapiens 40-45 27123832-5 2016 Consistent with this finding, silencing Stat3 by the specific shRNA or by the chemical inhibitor ruxolitinib results in drastic impediment of leukemia cell growth. ruxolitinib 97-108 signal transducer and activator of transcription 3 Homo sapiens 40-45 26981780-4 2016 The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage. ruxolitinib 20-31 signal transducer and activator of transcription 3 Homo sapiens 64-69 26811457-5 2016 In the present study the JAK1/2 inhibitor ruxolitinib reduced phosphorylation of STAT3 and STAT6 and expression of c-Myc in the HL cell line HDLM-2. ruxolitinib 42-53 signal transducer and activator of transcription 3 Homo sapiens 81-86 26701727-9 2016 Pharmacodynamic analysis showed that phosphorylation of STAT3 in the Ruxolitinib-treated tumor tissues was significantly suppressed. ruxolitinib 69-80 signal transducer and activator of transcription 3 Homo sapiens 56-61